A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
Latest Information Update: 03 Aug 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Registrational; Therapeutic Use
- Acronyms READY-3
- Sponsors Galderma Research & Development
- 30 Jul 2024 According to Galderma Media Release, the company announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for RelfydessTM (RelabotulinumtoxinA - previously referred to as QM1114). This positive decision, and the previous Therapeutic Goods Administration approval in Australia, were based on results from the phase III READY (RElabotulinumtoxin Aesthetic Development StudY) clinical trial program, which enrolled more than 1,900 participants.
- 12 Mar 2024 Results of Efficacy and safety , presented at the American Academy of Dermatology annual Meeting 2024
- 28 Feb 2024 According to Galderma Media Release, results from this study will be presented at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024